リスク警告: 当社の製品はレバレッジを使用しており、高いリスクが伴います。投資元本全額を失う可能性もあります。そのような製品はすべての投資家に適しているとは限りません。関連するリスクを十分に理解することが極めて重要です。
  • サポート
  • 機関投資家向け
リスク警告: 当社の製品はレバレッジを使用しており、高いリスクが伴います。投資元本全額を失う可能性もあります。そのような製品はすべての投資家に適しているとは限りません。関連するリスクを十分に理解することが極めて重要です。
  • サポート
  • 機関投資家向け

Current region:

  • 日本語
    ACTIVE
Other languages:
  • Español – Spanish
  • Português – Portuguese
  • English – International
  • 日本語 – Japanese
リスク警告: 当社の製品はレバレッジを使用しており、高いリスクが伴います。投資元本全額を失う可能性もあります。そのような製品はすべての投資家に適しているとは限りません。関連するリスクを十分に理解することが極めて重要です。
リスク警告:レバレッジ商品は高いリスクを伴い、投資元本をすべて失う可能性があります。投資を行う前に、リスクを十分に理解してください。
リスク警告:レバレッジ商品は高いリスクを伴い、投資元本をすべて失う可能性があります。投資を行う前に、リスクを十分に理解してください。

Current region:

  • 日本語
    ACTIVE
Other languages:
  • Español – Spanish
  • Português – Portuguese
  • English – International
  • 日本語 – Japanese

AMD, Palantir, and Super Micro Lead Today’s Stocks to Watch

U.S. stocks are in focus today as investors track key corporate updates across technology, healthcare, and energy. Palantir gained after raising its full-year forecast, while Hims came under pressure following its break with Novo Nordisk and weaker sales. BP also moved higher, supported by improved margins and fresh cost-cutting measures.

Key Points:

  • Palantir rises 6% after lifting its full-year forecast.
  • Hims dropped 10% following a break with Novo Nordisk and disappointing sales.
  • BP gains 2.5% on improved margins and announced cost cuts.

Palantir (PLTR): Momentum from Upward Guidance

Palantir gained 6% in premarket trading after reporting quarterly earnings that surpassed expectations and raising its full-year outlook. The company continues to benefit from growing demand for its AI-driven software offerings.

Hims & Hers (HIMS), Novo Nordisk (NVO): Declines on Partnership Fallout and Weak Results

Shares of Hims fell over 10% after missing revenue estimates. The stock was further pressured by tensions with Novo Nordisk, sparked by Hims’ offering of generic weight-loss medications via its platform.

Vertex Pharmaceuticals (VRTX): Setback Following Clinical Trial Decision

Vertex declined 14% in after-hours trading after announcing it will halt development of its experimental pain treatment, despite promising early-stage data. The decision underscores the company’s reliance on its late-stage pipeline.

DuPont de Nemours (DD): Strong Sales and Upbeat Outlook

DuPont rose 7% in premarket trading after exceeding sales projections and issuing guidance above analyst expectations. Its specialty materials division showed resilience amid uneven end-market demand.

BP (BP), Diageo (DEO): Gains Despite External Pressures

BP advanced 2.5% after reporting stronger profitability metrics and introducing additional cost-saving initiatives. Diageo added 2% despite forecasting a $200 million annual tariff impact.

Advanced Micro Devices (AMD), Super Micro (SMCI), Snap (SNAP): Key Earnings Ahead

Investors are watching earnings reports from AMD, Super Micro Computer, and Snap, all due Tuesday. These results will offer insight into demand trends for high-performance chips, server infrastructure, and social media platforms amid a still-recovering tech landscape.

Related posts

AUD Steady Despite China Trade Beat

AUD Steady Despite China Trade Beat

The Australian Dolla […]

Technical Analysis-EN

EURUSD Awaits ECB Rate Decision

The European Central […]

Featured-WeeklyOutlook-EN (1)

Weekly Market Outlook | 8–12 June

Global markets enter […]